ArticleInternational journal of obesity (2005)2026
A single centre retrospective study of the long‑term weight and pregnancy-related outcomes in women of reproductive age before and after liraglutide exposure.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of GLP‑1 receptor agonist exposure prior to pregnancy on pregnancy-related outcomes remains unclear, with studies reporting mixed findings.
methodsWe conducted a retrospective study evaluating bodyweight and pregnancy-related outcomes among women of reproductive age who were initiated on liraglutide for obesity management and had 2-5 years of follow-up. We compared pregnancies occurring before and after liraglutide exposure in the same women.
resultsA total of 556 women met the inclusion criteria of which 97 (17.4%) conceived and 459 (82.6%) did not conceive after liraglutide exposure. Baseline characteristics were comparable. After 2-5 years, the mean final weight change was significantly different between women who conceived compared to those who did not (+1.1 ± 11.3% vs. -6.7 ± 9.9%, p < 0.001). The nadir weight reduction on liraglutide in women who conceived was -6.2 ± 7.8%. Gestational weight change was similar in pre- and post-exposure pregnancies (8.0 ± 10.9% vs. 9.2 ± 11.8%, p = 0.554). Additionally, there were no differences in gestational diabetes (32.1% vs. 37.7%, p = 0.629), hypertensive disorders of pregnancy (9.2% vs. 0%, p = 0.063), need for c-section (33.3% vs. 38.9%, p = 0.549), pre-term delivery (3.7% vs. 1.9%, p = 0.500), large for gestational age (5.5% vs. 5.5%, p = 1) or small for gestational age infants (11.1% vs. 9.3%, p = 1) in pre- vs. post-exposure pregnancies. Subgroup analysis demonstrated a lower gestational weight gain with metformin use during pregnancy but was not statistically significant (5.8 ± 9.1 kg vs. 8.2 ± 9.5 kg, p = 0.369). The proportion of women with inconsistent obesity medication use during the study period was higher in those who conceived compared to those who did not (100% vs. 36.5%).
conclusionPreconception liraglutide exposure, followed by discontinuation before pregnancy, was associated with weight regain but not with excess gestational weight gain in our within-individual design. Despite a small sample size, we did not observe increased adverse gestational outcomes in the post-exposure pregnancies.
Indexed as
Identifiers
42174221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.